1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

08 May 2024
Admin
News Article

BioAtla Receives FDA Clearance for IND Application for BA3361

BioAtla Receives FDA Clearance for Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate Targeting Multiple Tumors

Overview

BioAtla, Inc. (Nasdaq: BCAB) has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with its investigational new drug (IND) application for BA3361 (CAB-Nectin-4), an antibody drug conjugate (ADC) aimed at treating various tumor types. This milestone marks a significant step forward in the development of innovative therapies for solid tumors.

ADCs

ADCs represent a promising avenue for treating a wide range of tumors, offering the potential for targeted therapy while minimizing off-target effects. BioAtla's CAB technology is specifically engineered to enhance the safety and efficacy of ADCs by reducing both on-target, off-tumor and off-target, off-tumor toxicities.

Data presented on AACR

At the recent AACR Annual Meeting in April 2024, BioAtla presented compelling data on BA3361, showcasing its differentiated approach to targeting Nectin-4.
Through innovative in vitro and in vivo studies, the company demonstrated the effectiveness of its NextGen carbohydrate linker system in minimizing off-target toxicity while improving serum stability and potency.
Notably, BA3361 exhibited complete tumor regression in various preclinical models and outperformed existing treatments in pancreatic cancer models, all while showing reduced toxicity due to CAB selectivity.

Nectin-4: A potential target

BioAtla, expressed enthusiasm for the FDA's clearance of BA3361, emphasizing the potential of Nectin-4 as a therapeutic target.
He highlighted the combination of CAB technology with the NextGen linker system as a means to maximize therapeutic benefits and broaden the scope of indications for this novel ADC.

Drug Molecules Target

BA3361, CAB-Nectin4-ADC, targets Nectin4, a cell-cell adhesion molecule overexpressed in various cancers. Engineered to be conditionally and reversibly active, BA3361 is designed to optimize binding under tumor microenvironment conditions while minimizing binding under normal physiological conditions.
It is the first of BioAtla's molecules to incorporate the NextGen ADC linker, enhancing stability and enabling tumor-specific payload release, leading to superior activity in preclinical models of pancreatic cancer.

BioAtla's progress with BA3361 underscores its commitment to advancing innovative therapies for cancer treatment, leveraging cutting-edge technology to address unmet medical needs and improve patient outcomes.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!